Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Prostate Cancer

  Free Subscription


06.07.2020

3 AJR Am J Roentgenol
1 Am J Clin Oncol
2 BJU Int
1 BMC Cancer
1 Br J Radiol
4 Eur Radiol
4 Eur Urol
1 Int J Cancer
1 J Magn Reson Imaging
1 J Natl Cancer Inst
2 J Urol
2 Lancet Oncol
1 Nat Rev Urol
1 Oncology (Williston Park)
1 PLoS One
1 Prog Urol
1 Prostate


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. BHARGAVA P, Ravizzini G, Chapin BF, Kundra V, et al
    Imaging Biochemical Recurrence After Prostatectomy: Where Are We Headed?
    AJR Am J Roentgenol. 2020 Mar 4:1-11. doi: 10.2214/AJR.19.21905.
    PubMed         Abstract available

  2. LEE DK, Sung DJ, Kim CS, Heo Y, et al
    Three-Dimensional Convolutional Neural Network for Prostate MRI Segmentation and Comparison of Prostate Volume Measurements by Use of Artificial Neural Network and Ellipsoid Formula.
    AJR Am J Roentgenol. 2020 Mar 24:1-10. doi: 10.2214/AJR.19.22254.
    PubMed         Abstract available

  3. ABREU-GOMEZ J, Wu M, McInnes MDF, Thornhill RE, et al
    Shape Analysis of Peripheral Zone Observations on Prostate DWI: Correlation to Histopathology Outcomes After Radical Prostatectomy.
    AJR Am J Roentgenol. 2020;214:1239-1247.
    PubMed         Abstract available


    Am J Clin Oncol

  4. MURALIDHAR V, Dee EC, D'Amico AV
    Sequencing Treatments for Cancer During the COVID-19 Pandemic.
    Am J Clin Oncol. 2020;43:457-458.
    PubMed        


    BJU Int

  5. MATTI B, Lyndon M, Zargar-Shoshtari K
    Ethnic and Socioeconomic disparities in Prostate Cancer Screening - Lessons from New Zealand.
    BJU Int. 2020 Jun 29. doi: 10.1111/bju.15155.
    PubMed         Abstract available

  6. CHEN MY, Franklin A, Yaxley J, Gianduzzo T, et al
    Solitary rib lesions showing PSMA uptake in pre-treatment staging (68) Ga-PSMA-11 PET scans for men with prostate cancer: benign or malignant?
    BJU Int. 2020 Jun 27. doi: 10.1111/bju.15152.
    PubMed         Abstract available


    BMC Cancer

  7. CASARIN S, Dondossola E
    An agent-based model of prostate Cancer bone metastasis progression and response to Radium223.
    BMC Cancer. 2020;20:605.
    PubMed         Abstract available


    Br J Radiol

  8. TAYLOR T, Richmond N
    A UK wide study of current prostate planning practice.
    Br J Radiol. 2020;93:20200142.
    PubMed         Abstract available


    Eur Radiol

  9. CUOCOLO R, Cipullo MB, Stanzione A, Romeo V, et al
    Machine learning for the identification of clinically significant prostate cancer on MRI: a meta-analysis.
    Eur Radiol. 2020 Jun 30. pii: 10.1007/s00330-020-07027.
    PubMed         Abstract available

  10. ULLRICH T, Arsov C, Quentin M, Mones F, et al
    Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a retrospective cohort study.
    Eur Radiol. 2020 Jun 26. pii: 10.1007/s00330-020-06997.
    PubMed         Abstract available

  11. ARIF M, Schoots IG, Castillo Tovar J, Bangma CH, et al
    Clinically significant prostate cancer detection and segmentation in low-risk patients using a convolutional neural network on multi-parametric MRI.
    Eur Radiol. 2020 Jun 27. pii: 10.1007/s00330-020-07008.
    PubMed         Abstract available

  12. DENIFFEL D, Abraham N, Namdar K, Dong X, et al
    Using decision curve analysis to benchmark performance of a magnetic resonance imaging-based deep learning model for prostate cancer risk assessment.
    Eur Radiol. 2020 Jun 26. pii: 10.1007/s00330-020-07030.
    PubMed         Abstract available


    Eur Urol

  13. BROOKMAN-MAY SD, May M
    Re: Androgen-deprivation Therapies for Prostate Cancer and Risk of Infection by SARS-CoV-2: A Population-based Study (n=4532).
    Eur Urol. 2020 Jun 16. pii: S0302-2838(20)30443.
    PubMed        

  14. TROYER D
    High-risk Prostate Cancer Patients Are Not All Alike.
    Eur Urol. 2020 Jun 27. pii: S0302-2838(20)30453.
    PubMed        

  15. CHIN JL, Bauman GS
    Re: Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
    Eur Urol. 2020 Jun 27. pii: S0302-2838(20)30445.
    PubMed        

  16. ABUFARAJ M, Iwata T, Kimura S, Haddad A, et al
    Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.
    Eur Urol. 2020 Jun 27. pii: S0302-2838(20)30429.
    PubMed         Abstract available


    Int J Cancer

  17. BORKOWETZ A, Froehner M, Rauner M, Conrad S, et al
    Neuropilin-2 is an independent prognostic factor for shorter cancer-specific survival in patients with acinar adenocarcinoma of the prostate.
    Int J Cancer. 2020;146:2619-2627.
    PubMed         Abstract available


    J Magn Reson Imaging

  18. TAMADA T, Kido A, Yamamoto A, Takeuchi M, et al
    Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1.
    J Magn Reson Imaging. 2020 Jul 2:e27283. doi: 10.1002/jmri.27283.
    PubMed         Abstract available


    J Natl Cancer Inst

  19. LEHRER S, Rheinstein PH
    Re: Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening.
    J Natl Cancer Inst. 2020 Jun 30. pii: 5865274. doi: 10.1093.
    PubMed        


    J Urol

  20. CLAROS OR, Tourinho-Barbosa RR, Fregeville A, Gallardo AC, et al
    Re: Comparison of Initial Experience with Transrectal Magnetic Resonance Imaging Cognitive Guided Micro-Ultrasound Biopsies versus Established Transperineal Robotic Ultrasound Magnetic Resonance Imaging Fusion Biopsies for Prostate Cancer.
    J Urol. 2020 May 5:101097JU0000000000001123. doi: 10.1097/JU.0000000000001123.
    PubMed        

  21. KINNAIRD A, Sharma V, Chuang R, Priester A, et al
    Risk of Prostate Cancer after a Negative MRI-Guided Biopsy.
    J Urol. 2020 Jul 2:101097JU0000000000001232. doi: 10.1097/JU.0000000000001232.
    PubMed         Abstract available


    Lancet Oncol

  22. CALAIS J, Ceci F, Eiber M, Hope TA, et al
    (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
    Lancet Oncol. 2019 Jul 30. pii: S1470-2045(19)30415.
    PubMed         Abstract available

  23. MADABHUSHI A, Feldman MD, Leo P
    Deep-learning approaches for Gleason grading of prostate biopsies.
    Lancet Oncol. 2020;21:187-189.
    PubMed        


    Nat Rev Urol

  24. PERERA M, Roberts MJ, Klotz L, Higano CS, et al
    Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer.
    Nat Rev Urol. 2020 Jun 30. pii: 10.1038/s41585-020-0335.
    PubMed         Abstract available


    Oncology (Williston Park)

  25. KUZNAR W
    Radical Prostatectomy as Primary Treatment for Prostate Cancer Leads to Better Survival.
    Oncology (Williston Park). 2020;34:228.
    PubMed         Abstract available


    PLoS One

  26. SILTARI A, Murtola TJ, Talala K, Taari K, et al
    Antihypertensive drug use and prostate cancer-specific mortality in Finnish men.
    PLoS One. 2020;15:e0234269.
    PubMed         Abstract available


    Prog Urol

  27. PERCOT M, Robert G, Bladou F, Ferriere JM, et al
    Active surveillance in prostate cancer is possible for Afro-Caribbean population: Comparison of oncological outcomes with a Caucasian cohort.
    Prog Urol. 2020 Jun 24. pii: S1166-7087(20)30185.
    PubMed         Abstract available


    Prostate

  28. RINELLA L, Pizzo B, Frairia R, Delsedime L, et al
    Modulating tumor reactive stroma by extracorporeal shock waves to control prostate cancer progression.
    Prostate. 2020 Jul 1. doi: 10.1002/pros.24037.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: